Zhitong Financial App News, Huiyu Pharmaceutical (688553.SH) issued an announcement. The company's subsidiary Seacross (Europe) Pharma Ltd. recently received a marketing license for the company's injectable paclitaxel (albumin binding type) approved and issued by the French National Drug and Health Product Safety Administration.

The main monotherapy with injectable paclitaxel (albumin combination) is suitable for treating adult patients with metastatic breast cancer (these patients have not improved after first-line treatment of metastatic disease, and standard anthracycline treatment plans are not applicable); use in combination with gemcitabine is suitable for the initial treatment of adult patients with metastatic pancreatic cancer; use in combination with carboplatin is suitable for the initial treatment of adult patients with non-small cell lung cancer who are unfit to undergo surgery and/or radiation therapy that may have curative effects.

The company's injectable paclitaxel (albumin binding type) has been successfully developed and registered in many countries, and has now obtained marketing licenses in 15 countries including the United Kingdom and France. Up to now, the company has applied for registration in Serbia.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.